Case Type: Mergers & Acquisitions

Finward Bancorp

Finward Bancorp (NASDAQ: FNWD) related to its sale to First Financial Bancorp. Under the terms of the proposed transaction, Finward shareholders are expected to receive 1.35 shares of First Financial common stock for each share of Finward common stock.

Personalis, Inc.

Personalis, Inc. (NASDAQ: PSNL) related to its sale to Tempus AI, Inc. Under the terms of the proposed transaction, Personalis shareholders are expected to receive $16.25 per share of common stock. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect payment in cash at Tempus’ discretion, … Read more

Standard Biotools Inc.

Standard Biotools Inc. (NASDAQ: LAB) related to its merger with Treeline Biosciences, Inc. Upon closing of the proposed transaction, Standard Biotools shareholders are expected to own approximately 16% of the combined company.

LXP Industrial Trust

LXP Industrial Trust (NYSE: LXP) related to its sale to Brookfield Asset Management and Canada Pension Plan Investment Board. Under the terms of the proposed transaction, LXP shareholders are expected to receive $61.20 per share in cash.

AtaiBeckley Inc.

AtaiBeckley Inc. (NASDAQ: ATAI) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, AtaiBeckley shareholders are expected to receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments upon achievement of specified … Read more

First Hawaiian, Inc.

First Hawaiian, Inc. (NASDAQ: FHB) related to its merger with TriCo Bancshares. Upon closing of the proposed transaction, First Hawaiian shareholders are expected to own approximately 65% of the combined company.

TriCo Bancshares

TriCo Bancshares (NASDAQ: TCBK) related to its sale to First Hawaiian, Inc. Upon closing of the proposed transaction, TriCo shareholders are expected to own approximately 35% of the combined company.

NextCure, Inc.

NextCure, Inc. (NASDAQ: NXTC) related to its merger with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately 1.21% of the combined company.